Login
← Go Back
Supriya Lifescience
SUPRIYA · Pharma > Pharmaceuticals & Drugs · Chairman: Satish Waman Wagh · MD: Satish Waman Wagh · Listing date: Dec. 29, 2021
Stock Price vs Company Growth
1d
4.7%
1w
1.2%
1m
5.7%
3m
15.5%
6m
83.7%
1y
164.7%
all
15.5%
🤔 How to analyze this graph?
Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price
₹ 729 4.7%
511
835
Company Overview
Sales
625 Cr
Growth: 15.9%
Profit after Tax
158 Cr
Growth: 16.5%
Small Cap
5,864 Cr
P/E: 37.3x
Industry P/E: 37.3x
Fundamentals
Sales (Cr) ₹ 625
Growth 15.9%
EBITDA 35.9%
P/S 9.4x
Dividend 0.2%
P/E 37.3x
Book Value ₹ 2
PEG Ratio 2.4x
ROE 978.5%
P/B N/A
Shareholding Pattern
Institutions
Promoters
Others
Increase    Decrease    No change
Company Profile Detailed
The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development. The company has niche product offerings of various APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic.
Belongs to (6 Indices) view more
Investors (5)
jyotsana
rajeev4
satish.w...